Form 8-K - Current report:
SEC Accession No. 0001104659-23-026402
Filing Date
2023-02-28
Accepted
2023-02-28 08:17:39
Documents
14
Period of Report
2023-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm237813d1_8k.htm   iXBRL 8-K 27457
2 EXHIBIT 99.1 tm237813d1_ex99-1.htm EX-99.1 82002
6 GRAPHIC tm237813d1_ex99-1img001.jpg GRAPHIC 4700
  Complete submission text file 0001104659-23-026402.txt   302629

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA knsa-20230228.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE knsa-20230228_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knsa-20230228_pre.xml EX-101.PRE 22593
8 EXTRACTED XBRL INSTANCE DOCUMENT tm237813d1_8k_htm.xml XML 3612
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100
Kiniksa Pharmaceuticals, Ltd. (Filer) CIK: 0001730430 (see all company filings)

EIN.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38492 | Film No.: 23678550
SIC: 2834 Pharmaceutical Preparations